Molecular biomarkers have been largely excluded from current management algorithms for urologic malignancies. This Review focuses on molecular biomarkers that could potentially be used to diagnose and prognose patients with bladder cancer, as well as markers with potential for forecasting and stratifying responses to emerging targeted therapies.